Core Viewpoint - The newly established fund, Dachen Xingyuan Qihang, managed by veteran fund manager Xu Yan, has faced criticism for its near-zero operation strategy amidst a rising market, leading to questions about its investment approach and performance [1][2][3]. Fund Performance and Strategy - Since its inception in March, Dachen Xingyuan Qihang has maintained a net value close to its face value, with a stock allocation of only 0.73% and cash making up 84.95% of its net value as of June 30 [2][3]. - Xu Yan acknowledged in the fund's mid-year report that the current market environment has changed significantly, necessitating a more cautious investment approach [1][4]. - As of September 11, the fund's A-class share net value reached 1.0035, marking a new high since its establishment, despite the fund's minimal stock holdings [1][3]. Market Context - The Shanghai Composite Index reached a new high of 3892.74 points on September 12, with many newly launched funds quickly building positions and achieving significant returns [1][2]. - In contrast, Dachen Xingyuan Qihang's lack of aggressive investment has led to investor frustration, especially as other funds have capitalized on the market rally [2][3]. Manager Background - Xu Yan, a seasoned fund manager with a history at Dachen Fund, has emphasized his focus on absolute returns rather than relative performance, managing a total fund size of 19.367 billion yuan as of the second quarter [5]. - His management style is characterized by low turnover rates and a focus on long-term value, with several of his funds achieving over 100% returns since he took over [5].

Core Viewpoint - Kanghong Pharmaceutical has experienced a decline in stock price over four consecutive trading days, with a cumulative drop of 8.09% [1] Company Overview - Chengdu Kanghong Pharmaceutical Group Co., Ltd. was established in 1996 and focuses on the research, production, sales, and after-sales service of biological products, traditional Chinese medicine, chemical drugs, and medical devices [1] - The company possesses advanced research and development centers and standardized industrial production bases, with a marketing network that spans the entire country [1] Shareholder Activity - Three funds under Dacheng Fund have entered the top ten shareholders of Kanghong Pharmaceutical, including: - Dacheng Strategy Return Mixed A, which increased its holdings in Q1 of this year - Dacheng Competitive Advantage Mixed A, which also increased its holdings in Q1 - Dacheng Rui Xiang Mixed A, which entered as a new shareholder in Q1 [1] - The performance of these funds in 2023 is as follows: - Dacheng Strategy Return Mixed A: 1.46% return, ranking 2872 out of 4548 - Dacheng Competitive Advantage Mixed A: 4.62% return, ranking 1825 out of 4548 - Dacheng Rui Xiang Mixed A: 2.35% return, ranking 2545 out of 4548 [1] Fund Management - The fund manager for Dacheng Strategy Return Mixed A, Dacheng Competitive Advantage Mixed A, and Dacheng Rui Xiang Mixed A is Xu Yan [5][7] - Xu Yan holds a master's degree in management from Fudan University and has extensive experience in fund management, having worked at Dacheng Fund Management Co., Ltd. since 2007 [6]